We sought to determine if beta-blocker therapy improves clinical outcomes of acute myocardial infarction (AMI) after successful primary percutaneous coronary intervention (PCI). BACKGROUND We have shown that pre-treatment with beta-blockers has a beneficial effect on short-term clinical outcomes in patients undergoing primary PCI for AMI. It is unknown if beta-blocker therapy after successful primary PCI improves prognosis of AMI.
The American College of Cardiology/American Heart Association guidelines recommend routine use of betablockers after acute myocardial infarction (AMI) (1) . This recommendation is based on results of studies performed in the pre-fibrinolytic era (2) (3) (4) (5) (6) and in patients treated with thrombolytics (7) (8) (9) (10) (11) . In the era of primary angioplasty, no clinical trials have examined the independent impact of See page 1788 beta-blockers on clinical outcomes after successful primary percutaneous coronary intervention (PCI) for AMI. Recently, we reported improved short-term clinical outcomes when beta-blockers are given for AMI before primary PCI (12) . We believe that the benefit from pre-treatment with beta-blockers is likely due to attenuation of the harmful enhanced sympathetic drive that causes tachycardia, hypertension, and increased myocardial stress during AMI. It is less clear, however, if beta-blockade after successful primary PCI improves prognosis. To address this hypothesis, we analyzed patients enrolled in the Primary Angioplasty in Acute Myocardial Infarction-2 (PAMI-2), No Surgery-onSite (noSOS), Stent PAMI, and Air PAMI trials.
METHODS
Study population. We pooled clinical, angiographic, and clinical outcome data from 2,442 patients who underwent successful primary PCI in the PAMI-2 (13, 14) , noSOS (15) , Stent-PAMI (16, 17) , and Air-PAMI trials (18) (Table 1). The PAMI studies without data on post-PCI beta-blocker use were not included. Successful PCI was defined as achievement of Thrombolysis In Myocardial Infarction (TIMI) 3 flow and final residual stenosis Ͻ50% in the infarct-related artery (IRA). Left ventricular ejection fraction (LVEF) was determined by left ventriculography at the time of emergent cardiac catheterization. We excluded 475 patients with unsuccessful PCI from the analysis. A total of 1,661 patients received post-procedural betablockers, and 781 patients did not. PAMI study protocol. All patients enrolled presented within 12 h of onset of chest pain and electrocardiographic changes (ST elevation in two contiguous leads or left bundle branch block). The trials excluded patients presenting with cardiogenic shock, those with high bleeding risk, and those who did not give informed consent. Before PCI, patients received 325 mg chewable aspirin, a 5,000-to 10,000-U bolus of heparin, and nitroglycerin. Intravenous beta-blockers were recommended for all patients without contraindications in all studies. Patients were taken emergently to the cardiac cath lab for coronary angiography and possible intervention. Those patients deemed unlikely to benefit from primary PCI (IRA with Յ70% stenosis or supplying a small area of myocardium) were treated medically without mechanical intervention. Patients found to have unprotected left main stenosis Ͼ60% or severe proximal three-vessel coronary artery disease (CAD) and spontaneous reperfusion were referred for coronary artery bypass grafting (CABG). In the absence of these contraindications, patients underwent PCI. Patients undergoing PCI were given heparin to achieve an activated clotting time between 350 and 400 s. Study monitors recorded in-hospital and six-month follow-up events at each center from review of patient medical records and, if indicated, telephone contact with the patient or family. Study outcome. We classified patients into beta group (those who received beta-blockers after successful PCI, n ϭ 1,661) and no-beta group (those who did not receive beta-blockers after PCI, n ϭ 781). We compared baseline clinical and angiographic characteristics of both groups and assessed the incidence of death and major adverse cardiac events (MACE) (death, reinfarction, and ischemic-driven target vessel revascularization) at six months. Statistics. Statistical analyses were completed on the categorical variables using a chi-square test where appropriate (expected frequency Ն5); otherwise a Fisher exact test was used. Continuous variables were examined using a Wilcoxon rank test. This is a nonparametric approximation of the t test. Kaplan-Meier survival curves were created for the cumulative incidence for death at six months comparing beta versus no-beta groups with a log-rank test.
A propensity score was derived using step-down logistic regression analyses to determine predictors of beta-blocker use after successful PCI. It adjusted for variables including age Ͼ70, history of peripheral vascular disease (PVD), final IRA percent stenosis, prior CABG, and having a right coronary artery (RCA) infarct. This score was included along with beta-blocker use in further multivariate analyses to adjust for the likelihood that a given patient would receive beta-blockers post-PCI. The SAS version 8.0 (Cary, North Carolina) was used for all analyses.
To determine the independent correlation of betablocker use with death and MACE at six months, we performed step-down logistic regression analyses. Clinical and angiographic differences (age, gender, current smoker, history of diabetes, PVD or chronic obstructive lung disease, prior angina, PCI, stent or CABG, Killip class Ͼ1, multivessel CAD, EF Յ50% [operator defined], final residual stenosis, systolic blood pressure Ͻ100, or IRA in the left circumflex or RCA; p Ͻ 0.10) and the propensity score were used as potential covariates in the models. Similar analyses were performed in the following subgroups: LVEF Յ50%, n ϭ 1,361; multi-vessel CAD, n ϭ 1,124; and those who survived index hospitalization without MACE, n ϭ 2,323.
RESULTS
Beta-blocker use. Of the 2,442 patients who had successful primary PCI, 1,661 patients (68%) were given betablockers after PCI. Across the four PAMI studies, the percent of patients given beta-blockers post-PCI ranged from 53% (Air PAMI) to 82% (NoSOS).
Abbreviations and Acronyms
AMI ϭ acute myocardial infarction CABG ϭ coronary artery bypass grafting CAD ϭ coronary artery disease IRA ϭ infarct-related artery I-TVR ϭ ischemia driven target vessel revascularization LVEF ϭ left ventricular ejection fraction MACE ϭ major adverse cardiac events PAMI ϭ Primary Angioplasty in Acute Myocardial Infarction PCI ϭ percutaneous coronary intervention PVD ϭ peripheral vascular disease RCA ϭ right coronary artery TIMI ϭ Thrombolysis in Myocardial Infarction Baseline characteristics. Beta patients were younger; they less frequently had a history of prior angina, CABG, PCI, diabetes, chronic obstructive lung disease (COPD), PVD, or admission Killip class Ͼ1; and they were more likely to be taking beta-blockers before emergent cardiac catheterization (Table 2) . Patients receiving beta-blockers less commonly had in-hospital sustained hypotension (4% in beta group vs. 8% in no-beta group, p ϭ 0.0004) and in-hospital Killip class Ͼ1 (7% in beta group vs. 10% in no-beta group, p ϭ 0.039), although in-hospital bradycardia occurred with equal frequencies in both groups (2.6% in beta group vs. 2.4% in no-beta group). Angiographically, the beta group Beta-Blockers After Successful Primary Angioplasty had a slightly lower final diameter stenosis and the IRA was the RCA more frequently ( Table 3 ).
The relation of beta-blocker use with six-month clinical outcomes.
Patients receiving beta-blocker therapy after primary PCI had lower six-month mortality (2.2% vs. 6.6%, p Ͻ 0.0001) and MACE (14% vs. 17%, p ϭ 0.036) compared with patients without beta-blocker use ( Fig. 1 and Table 4 ). In survival analysis, six-month death and MACE were lower in the beta group (log-rank p Ͻ 0.0001 for death, p ϭ 0.12) (Fig. 2) . After adjusting for baseline clinical and angiographic differences and propensity score, step-down multivariate Cox regression analyses showed that beta-blocker use was a significant independent predictor of lower six-month mortality (OR 0.43, 95% CI 0.26 to 0.73, p ϭ 0.0016), but not MACE (OR 0.87, 95% CI 0.66 to 1.13, p ϭ 0.29). Other variables independently associated with increased six-month mortality included EF Յ50%, multi-vessel CAD, age, history of PVD, Killip class Ͼ1, and a non-RCA (Fig. 3) . Subset analysis. (Fig. 1) . After excluding patients with in-hospital MACE beta group, n ϭ 1,562; no-beta group, n ϭ 727), beta patients (all patients included) were less likely to die at six months (1.0% vs. 2.1%, p ϭ 0.042) and had a trend toward lower MACE (9% vs. 11%, p ϭ 0.10) (Fig. 1) .
Patients receiving beta-blockers had higher survival and MACE-free survival at six months (Fig. 2) . In patients with EF Յ50%, beta-blockers were significant independent predictors of lower six-month mortality (OR 0.34, 95% CI 0.19 to 0.60, p ϭ 0.0002) but not MACE (OR 0.80, 95% CI 0.58 to 1.10, p ϭ 0.17). In patients with multi-vessel CAD, beta-blockers were significant independent predictors of lower six-month mortality (OR 0.26, 95% CI 0.14 to 0.48, p Ͻ 0.0001) and MACE (OR 0.57, 95% CI 0.41 to 0.80, p ϭ 0.0011). Beta-blocker therapy had a modest but nonsignificant independent effect on six-month clinical outcomes in patients who survived the index hospitalization without MACE (death: OR 0.58, 95% CI 0.29 to 1.17, p ϭ 0.13; MACE: OR 0.80, 95% CI 0.59 to 1.10, p ϭ 0.17).
DISCUSSION
Beta-blocker therapy imparts a significant six-month mortality benefit when given to AMI patients after successful primary PCI. Beta-blockade was associated with an absolute risk reduction of 4.4% in six-month mortality (2.2% in beta group vs. 6.6% in no-beta group); indicating that treating 23 patients prevented one death at six months. Previous largescale trials have also demonstrated reductions in mortality with beta-blocker therapy before and after primary fibrinolysis in the management of AMI. Teo et al. (7) reported a 1.2% absolute risk reduction (5.4% with beta-blockers vs. 6.6% without beta-blockers), which translates into one life saved per 83 patients treated. In multivariate analyses, beta-blockers were independently associated with lower mortality. We believe that our study is the first to show significant benefit from beta-blocker therapy even after successful primary angioplasty.
Further analyses revealed that two patient subgroups drove this benefit: patients with EF Յ50% and patients with multi-vessel CAD. Six-month mortality and MACE were lower in beta patients in each of these subgroups. In patients with low EF an absolute risk reduction of 5% for six-month mortality and 4% for six-month MACE was seen from beta-blocker therapy. In patients with multi-vessel CAD, absolute risk reductions of 7.3% for six-month mortality and 8% for six-month MACE were observed from beta-blocker therapy. Interestingly, these are larger reductions than the 3.8% absolute risk reduction in one-year mortality reported in a recent meta-analysis of beta-adrenergic blocker therapy for New York Heart Association functional class II and III congestive heart failure patients (19) . This significant mortality reduction in patients with either reduced EF or multi-vessel CAD is not surprising. Multiple large trials, including the meta-analysis by Brophy et al. (19) , have documented improvement in clinical outcomes seen with beta-adrenergic blockade in patients with left ventricular systolic dysfunction, with or without congestive heart failure (11, 20) . The data on beta-blockers in patients with multi-vessel versus single-vessel CAD, however, are less well established. Given their well-documented anti-ischemic and antiarrhythmic properties, beta-blockers might be expected to improve clinical outcomes across all these subgroups, especially with multi-vessel CAD where untreated coronary lesions in non-infarct-related arteries remain.
Patients with normal EF and those with single-vessel CAD showed no statistically significant reduction in sixmonth mortality or MACE with post-PCI beta-blockade, although mortality reduction may be clinically significant in patients with single-vessel CAD (1.8% vs. 2.9%). Given the wealth of data supporting beneficial effects of beta-blockers Kernis et al. May 19, 2004 May 19, :1773 Beta-Blockers After Successful Primary Angioplasty on long-term clinical outcomes, this observation may be at odds with intuitive expectation. However, no previous similar studies analyzed this large subgroup of AMI patients treated successfully with primary PCI. It is enticing to speculate that complete and successful primary revascularization early in the course of AMI in patients with normal LVEF reduces their future risk of cardiac events to a point where chronic beta-blockade becomes unnecessary. Although our retrospective study does not allow such a conclusion to be made definitively, we find this possibility intriguing. It is possible that the improved prognosis seen in beta patients was in large part due to a selection bias favoring use of beta-blockers in healthier patients (those with less frequent histories of CAD, chronic obstructive lung disease, and diabetes). Patients with sustained hypotension, CHF, and bradycardia during the index hospitalization, for example, are generally not treated with beta-blockers. In fact, we did find that a lower percentage of patients in the beta group experienced in-hospital sustained hypotension and Killip class Ͼ1, although both groups had equal incidences of in-hospital bradycardia. We minimized this selection bias by performing a subgroup analysis on patients without in-hospital MACE. This analysis showed that even in patients without in-hospital MACE, those receiving betablockers were less likely to die at six months. In multivariate analysis of patients without in-hospital MACE, betablockers were associated with a nonsignificant yet modest independent effect on six-month mortality. The OR of 0.58 in this subset is quite similar to the OR of 0.43 for the entire population. Hence, lack of statistical significance is likely secondary to fewer patients and fewer events in this subgroup. Study limitations. Our study has the usual limitations inherent to retrospective analyses; for example, selection bias may have led healthier patients to receive beta-blockers. Further, our results cannot be extrapolated to patients with cardiogenic shock, as the PAMI studies excluded these patients. Our results may be less representative of contemporary practice because of lower rates of glycoprotein IIb/IIIa and thienopyridine medications and lower stent use in the PAMI studies. We have no data on the specific beta-blocker used, the dose employed, or whether adequate beta-blockade was achieved. Summary. We have shown that AMI patients receiving beta-blockers after primary PCI have lower six-month mortality and MACE. Beta-blockade is independently associated with reduced six-month mortality, but not MACE. This benefit is driven by patients with reduced EF or multi-vessel CAD.
Our conclusions support the current American College of Cardiology/American Heart Association guidelines recommending beta-blocker therapy for secondary prevention after AMI. Whether beta-blockers are necessary after successful primary PCI for AMI in patients with normal EF or single-vessel CAD is a question that needs to be answered by future prospective clinical trials.
